SCHEMBL7072145

SCHEMBL7072145

CC(C)(C)OC(=O)c1ccc(C=O)c([N+](=O)[O-])c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.46
VCAM1 P19320 1/20 0.46
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
ALOX15 P16050 1/20 0.43
PRKDC P78527 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HPGD P15428 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MET P08581 1/20 0.42
TSHR P16473 1/20 0.40
KMT2A Q03164 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CASP6 P55212 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10061493 0.89 ERN1 (0.46) ERN1VCAM1ALDH1A1MAPTKDM4E
SCHEMBL192836 0.84 ERN1 (0.62) ERN1VCAM1ALDH1A1MAPTKDM4E
SCHEMBL11247732 0.84 CASP6 (0.57) VCAM1ALDH1A1MAPTCYP3A4HPGD
SCHEMBL9272516 0.82 ALDH1A1 (0.48) ERN1ALDH1A1MAPTKDM4ECYP3A4
SCHEMBL1026971 0.81 TSHR (0.62) VCAM1ALDH1A1MAPTKDM4EHPGD
SCHEMBL1186419 0.81 VCAM1 (0.49) VCAM1ALDH1A1MAPTKDM4EALOX15
SCHEMBL3598047 0.81 KMT2A (0.61) ERN1ALDH1A1MAPTKDM4EHPGD
SCHEMBL2983672 0.80 PARP1 (0.59) VCAM1ALDH1A1MAPTKDM4EHPGD
SCHEMBL22230563 0.80 VCAM1 (0.48) VCAM1ALDH1A1MAPTHPGDNPSR1
SCHEMBL1570007 0.80 ITGB1 (0.53) VCAM1ALDH1A1MAPTHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin WYETH (US) 2003-06-12 US disclosed
US-6429214-B1 INHIBITORS OF BONE RESORPTION WYETH 2002-08-06 US disclosed
EP-1198231-A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN AMERICAN HOME PRODUCTS CORPORATION (US) 2002-04-24 EP disclosed
WO-2001007036-A1 BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109523-A1 Bicyclic antagonists selective for the alphavbeta3 integrin ITGAV, ITGB2, ITGB3 ERN1 4084/4885VCAM1 35/4885ALDH1A1 1467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.